This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reilly, J. J. Articles by Emmett, P. M. Search for Related Content PubMed PubMed Citation Articles by Reilly, J. J. Articles by Emmett, P. M.

Premature Adiposity Rebound in Children Treated for Acute Lymphoblastic Leukemia*

University Departments of Human Nutrition (J.J.R., A.K., P.N., A.R.D.) and Haematology (B.E.S.G.), Yorkhill Hospitals, Glasgow G3 8SJ; Department of Paediatric Haematology and Oncology (W.H.B.W.), Royal Hospital for Sick Children, Edinburgh EH9 1LF; and Unit of Paediatric and Perinatal Epidemiology, Institute of Child Health (P.M.E., ALSPAC Study Team), University of Bristol, Bristol BS8 1TQ, United Kingdom

Address correspondence and requests for reprints to: Dr. John J. Reilly, University Department of Human Nutrition, Yorkhill Hospitals, University of Glasgow, Glasgow G3 8SJ, United Kingdom. E-mail: jjr2y{at}clinmed.gla.ac.uk * ALSPAC was supported by the Wellcome

Abstract

The adiposity rebound (AR), when body mass index begins to increase after its nadir in childhood, is a critical period for the regulation of energy balance and adult obesity risk. The aim of the present study was to test whether children treated for acute lymphoblastic leukemia (ALL) experience premature AR. This might, in part, explain their tendency to develop obesity. Timing of AR was assessed by visual inspection of body mass index plots in 68 patients treated for ALL in first remission. This sample comprised all eligible patients treated in Scotland between 1991 and 1998, age 30 months or less at the time of diagnosis. Timing of AR in patients was compared against a cohort of 889 healthy British children studied during the 1990s using the same method. AR occurred significantly earlier in the patients treated for ALL (² test, P < 0.001). The AR had occurred in 43% (29 of 68) of the patients and 4% (40 of 889) of the comparison group by age 37 months. At 49 months AR had occurred in 81% (55 of 68) of the patients and 21% (190 of 889) of the comparison group. Treatment of ALL is associated with a significantly advanced AR. This might, in part, explain the extremely high prevalence of obesity in long-term survivors. Clinical management should focus on minimizing excess weight gain during therapy to reduce long-term obesity risk.

This article has been cited by other articles:

				J. C K Wells and M. S Fewtrell Is body composition important for paediatricians? Arch. Dis. Child., February 1, 2008; 93(2): 168 - 172. [Abstract] [Full Text] [PDF]